JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web browser. It makes web pages functional for specific purposes and if disabled for some reason, the content or the functionality of the web page can be limited or unavailable.

Wednesday, July 23, 2025

New cancer therapy available in T&T

by

20140412

The Chem­istry, Food and Drugs Di­vi­sion of the Min­istry of Health ap­proved the in­tro­duc­tion of Abi­raterone Ac­etate to the coun­try, the first oral­ly ad­min­is­tered med­ica­tion for the treat­ment of pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer.Clin­i­cal tri­als have demon­strat­ed that this new ther­a­peu­tic re­source for the stan­dard ther­a­py of pa­tients with hor­mone-re­sis­tant tu­mors re­duces the risk of death by ap­prox­i­mate­ly 35 per cent. Abi­raterone Ac­etate is avail­able in T&T un­der the trade­mark Zyti­ga�.

Ac­cord­ing to the Na­tion­al Can­cer Reg­istry, prostate can­cer leads can­cer sta­tis­tics in the T&T pop­u­la­tion with 22 per cent of all cas­es. Among males, prostate can­cer ac­count­ed for 42 per cent of all new cas­es of can­cer. World­wide, prostate can­cer is the sec­ond type of can­cer most fre­quent­ly di­ag­nosed in men, and the fifth type over­all. Near 1.1 mil­lion new cas­es of prostate can­cer were di­ag­nosed world­wide in 2012, and more than 300,000 men died be­cause of the dis­ease.

This type of can­cer is the re­sult of the ma­lig­nant trans­for­ma­tion of cer­tain cells of the prostate, a gland lo­cat­ed un­der­neath the uri­nary blad­der in men, one of the func­tions of which is to pro­duce a part of the sem­i­nal flu­id. Al­though a slow­ly de­vel­op­ing dis­ease, some prostate tu­mours may be very ag­gres­sive and ex­tend quick­ly to in­vade oth­er or­gans.

Abi­raterone Ac­etate is ad­min­is­tered oral­ly as a sin­gle dai­ly dose, which pre­vents an­dro­gens from be­ing pro­duced at their three sources: Testes, adren­al glands, and the tu­mour it­self, through the strong block of the CYP 17 en­zyme. An­dro­gens are hor­mones that pro­mote male de­vel­op­ment and sex­u­al fea­tures, and prostate can­cer cells have been shown to need them to grow.

"Abi­raterone Ac­etate is an an­dro­gen syn­the­sis in­hibitor (testos­terone) treat­ment that re­duces the risk of death by ap­prox­i­mate­ly 35 per cent of pa­tients al­ready treat­ed with hor­mone ther­a­py and chemother­a­py. Ap­prox­i­mate­ly 20 per cent of all pa­tients with prostate can­cer progress to a se­vere stage of the dis­ease and could now ben­e­fit from this new ther­a­peu­tic al­ter­na­tive," said Dr Car­men Mar­tinez, med­ical di­rec­tor of Janssen for Venezuela, Cen­tral Amer­i­ca and the Caribbean.

One of the most salient as­pects of Abi­raterone Ac­etate that dis­tin­guish­es it from oth­er on­co­log­ic treat­ments is that it pos­sess­es a nov­el mech­a­nism of ac­tion, with a ben­e­fit as to the over­all sur­vival rate, and a tol­er­a­ble tox­i­c­i­ty pro­file.


Related articles

Sponsored

Weather

PORT OF SPAIN WEATHER

Sponsored